Holen Sie sich die Stockscreener-App
2.66
0.00%
0.04
Schlusskurs vom Vortag:
$2.70
Offen:
$2.72
24-Stunden-Volumen:
24,446
Relative Volume:
0.14
Marktkapitalisierung:
$89.18M
Einnahmen:
$210.00K
Nettoeinkommen (Verlust:
$-10.40M
KGV:
-8.4471
EPS:
-0.3149
Netto-Cashflow:
$-6.88M
1W Leistung:
-2.53%
1M Leistung:
-11.18%
6M Leistung:
-20.59%
1J Leistung:
-14.29%
1-Tages-Spanne:
$2.66
$2.75
1-Wochen-Bereich:
$2.45
$2.89
52-Wochen-Spanne:
$2.331
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Firmenname
Anixa Biosciences Inc
Sektor
Branche
Telefon
408-708-9808
Adresse
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.66 | 90.53M | 210.00K | -10.40M | -6.88M | -0.3149 |
VRTX
Vertex Pharmaceuticals Inc
|
452.38 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.66 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.83 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.12 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.06 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Eingeleitet | Maxim Group | Buy |
| 2022-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-04-12 | Eingeleitet | H.C. Wainwright | Buy |
Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten
Earnings Recap: Whats the beta of Anixa Biosciences Inc stockPortfolio Performance Report & Technical Pattern Based Buy Signals - baoquankhu1.vn
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Exclusive: Anixa Biosciences' ovarian cancer drug candidate shows longer survival with no major safety issues - MSN
Anixa Biosciences (NASDAQ:ANIX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress - MarketBeat
Can Anixa Biosciences Inc keep up with sector leadersTrade Risk Assessment & Verified Stock Trade Ideas - baoquankhu1.vn
Anixa Biosciences Featured on Water Tower Research Healthcare Ha - GuruFocus
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast - PR Newswire
Experimental breast cancer vaccine shows positive data, Anixa CEO says - Stock Titan
Anixa Biosciences Shareholders Back Board and Compensation - TipRanks
Anixa Biosciences (NASDAQ: ANIX) investors approve directors, pay and auditor - Stock Titan
Anixa Biosciences, Inc. (ANIX) Shareholder/Analyst CallSlideshow (NASDAQ:ANIX) 2026-03-11 - Seeking Alpha
Anixa Biosciences : 2026 Annual Meeting of Shareholders Presentation - marketscreener.com
Anixa Biosciences Inc. Q1 2026 Financial Report: Earnings, Balance Sheet, and Key Disclosures - Minichart
Anixa receives Korean patent allowance for breast cancer vaccine By Investing.com - Investing.com Canada
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology - irw-press.com
Anixa Biosciences Inc reports results for the quarter ended January 31Earnings Summary - TradingView
ANIXA BIOSCIENCES ($ANIX) Releases Q1 2026 Earnings - Quiver Quantitative
Anixa Biosciences (NASDAQ:ANIX) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Anixa 10-Q: $0 Revenue, $(0.08) EPS for Q3 (Jan 31, 2026) - TradingView
Anixa Biosciences (NASDAQ: ANIX) narrows loss and advances cancer vaccine and CAR-T programs - Stock Titan
Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2026 - marketscreener.com
Anixa Biosciences Receives Notice of Allowance from Korean Minis - GuruFocus
Anixa Biosciences (ANIX) Secures Patent in South Korea for Breas - GuruFocus
Anixa receives Korean patent allowance for breast cancer vaccine - Investing.com
Anixa Biosciences (NASDAQ:ANIX) Upgraded to Hold at Wall Street Zen - MarketBeat
Anixa Biosciences Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ANIX SEC FilingsAnixa Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ANIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Anixa Biosciences (ANIX) to Release Earnings on Tuesday - MarketBeat
Anixa Biosciences to host 2026 annual meeting of stockholders and provide corporate update highlighting recent clinical and regulatory progress - marketscreener.com
Anixa Biosciences To Host 2026 Annual Meeting Of Stockholders And Provide Corporate Update Highlighting Recent Clinical And Regulatory Progress - TradingView
Anixa to outline ovarian CAR-T survival, breast cancer vaccine data - Stock Titan
Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat - Investing News Network
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote - GuruFocus
Co-inventor of Anixa cancer CAR-T to headline 2026 cell therapy retreat - Stock Titan
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic - Intellectia AI
Can Anixa Biosciences Inc. stock double in the next yearJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - mfd.ru
ANIX: Robust 2025 Milestones Set the Stage for a Pivotal 2026 - Smartkarma
Anixa Biosciences to Present at the iAccess Alpha Virtual Best I - GuruFocus
Whale Trades: Will Anixa Biosciences Inc. stock reach all time highs in 2025 - mfd.ru
Breast cancer vaccine now in early clinical trials: What to know - abcnews.com
Will Anixa Biosciences Inc. stock reach all time highs in 20252025 Price Targets & Community Consensus Trade Alerts - mfd.ru
Why Anixa Biosciences Inc. stock is seen as undervalued2025 Fundamental Recap & Reliable Breakout Forecasts - mfd.ru
Anixa Biosciences Updates Ovarian Cancer CAR-T Trial Outcomes - Intellectia AI
Aug Momentum: Can Anixa Biosciences Inc maintain its current growth rate2025 Valuation Update & Weekly High Return Stock Forecasts - baoquankhu1.vn
Can Anixa Biosciences Inc. keep up with sector leadersJuly 2025 Sentiment & Risk Managed Investment Entry Signals - mfd.ru
Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance - MarketBeat
ANIX: Pivotal data from advanced cancer trials and fiscal discipline set the stage for a transformative 2026 - TradingView
Anixa reports promising survival data in ovarian cancer CAR-T trial - Investing.com Australia
Finanzdaten der Anixa Biosciences Inc-Aktie (ANIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anixa Biosciences Inc-Aktie (ANIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Dec 15 '25 |
Option Exercise |
2.92 |
16,000 |
46,720 |
969,334 |
| KUMAR AMIT | Chief Executive Officer |
Oct 30 '25 |
Option Exercise |
2.92 |
200,000 |
584,000 |
779,925 |
| Titterton Lewis H jr | Director |
Jul 31 '25 |
Buy |
3.08 |
10,000 |
30,800 |
953,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):